Inovio Pharmaceuticals (INO) vs NRX Pharmaceuticals (NRXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Inovio Pharmaceuticals (INO) over the past year, losing 19.3% versus a loss of 57.4%. Over five years, NRXP leads with a -97.2% price change compared with -98.7% for INO. NRX Pharmaceuticals is the larger company by market cap ($125.1 million vs $112.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INO | NRXP |
|---|---|---|
| Share price | $1.09 | $2.89 |
| Market cap | $112.70M | $125.12M |
| 1-day change | -5.63% | -0.34% |
| YTD return | -37.36% | +6.64% |
| 1-year return | -57.42% | -19.27% |
| 5-year return | -98.71% | -97.18% |
| EPS (TTM) | $-0.90 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.72 | $5.06 |
| 52-week low | $0.56 | $1.62 |
| Distance from 52-week high | -59.93% | -42.83% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +190.83% | +1232.18% |
| Average volume | 3.86M | 865.49K |
| Shares outstanding | 103.40M | 43.30M |
| Employees | 112 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed INO by 38.1 percentage points over the past year.
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Health Care · Biotechnology: Pharmaceutical Preparations · 112 employees
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
INO vs NRXP FAQ
Which is bigger, Inovio Pharmaceuticals or NRX Pharmaceuticals?
NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $125.12M compared with $112.70M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, INO or NRXP?
NRXP returned -19.27% over the past 12 months, compared with -57.42% for INO (price return, excluding dividends). Past performance does not predict future results.
Are Inovio Pharmaceuticals and NRX Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.